amendment2.pdf
PDF 42 KB Posted
- Attached to
- Cancer Prevention Agent Development Program: Early Phase Clinical Research Federal contract opportunity
- Solicitation number
- N01CN05014-69
View the file
Other files for this federal contract opportunity
| File | Type | Posted |
|---|---|---|
| Amendment_3_Attachment_1_InformationAndPhysicalAccessSecurity.pdf | ||
| amendment3.pdf | ||
| Transcript_of_Preproposal_Conference_Held_04272011.pdf | ||
| ATTACHMENT_1_PACKAGINGANDDELIVERYOFTHEPROPOSAL_05042011.pdf | ||
| amendment1.pdf | ||
| Attachment_1_PACKAGING_AND_DELIVERY_OF_PROPOSALS_revised.pdf | ||
| N01CN05014-69.pdf | ||
| RFPAttachmentNondisclosure.pdf | ||
| Attachment_3_Statement_of_Work.pdf | ||
| Attachment_1_PACKAGING_AND_DELIVERY_OF_PROPOSALS.pdf |
On GovTribe
Work with this file on GovTribe
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
RFP Number : N01CN05014-69 Amendment 2
- 1 -
Amendment 2
OFFICE OF ACQUISITIONS
NATIONAL CANCER INSTITUTE
REQUEST FOR PROPOSAL NUMBER: N01CN05014-69
Amendment No.: 2
Date of Issuance: May 5, 2011
The above numbered Request For Proposal (RFP) is amended as set forth below. The hour and date specified for receipt of proposals remains unchanged.
Offerors MUST acknowledge receipt of the amendment prior to the hour and the date specified in the solicitation or as amended, by separate letter, telegram, or Electronic Mail which includes a reference to the RFP and Amendment number(s). For your convenience, the Proposal Intent Response Form is provided in SECTION J - List of Attachments of this RFP, for this purpose.
FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERORS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER.
This Amendment revises the RFP as stated below:
All contact regarding the solicitation must be through the Contracting Officers - Primary Point of Contact: Donna Perry-Lalley at perryd@mail.nih.gov Alternate Point of Contact: Virginia DeSeau at vd9t@nih.gov
A pre-proposal conference was held April 27, 2011. A transcript of that conference is attached to this amendment. Responses to questions submitted prior to and during the conference are provided in the attached transcript. The questions and responses provided below are clarifications of the questions in the transcript and, in some cases, new questions that were asked after the Pre-Proposal conference.
RFP Section J, Attachment 1, Packaging and Delivery of only hard copies is deleted and replaced in its entirety with Packaging and Delivery of two original hard copies and CDs for all other copies. See the new Attachment 1 document which is attached to this amendment for further instructions.
ADDITIONAL QUESTIONS
1. For the LOIs that we have to submit with the Technical Proposal, page 75, no budget template is given that should be submitted with each LOI. The only statement is "provide a detailed budget". Does it matter if we use the template suggested for protocol submissions or is it allowable for us to use the budget in the format that we usually submit [referring to templates/formats used by current contractors]?
NCI Response: You should develop the budgets for the sample LOIs using the information provided in the Additional Business Proposal Instructions as to the costs that will be allowed under "Per Protocol" and "Per Subject" costs. You may use the Excel spreadsheet provided in Section J, Attachment 11 as a template for the LOI budgets as well as the overall budgets, customizing them to adhere to the Additional Business Proposal Instructions.
2. On page 19 of the transcript, someone asked DCP to "identify which drugs are available in the NCI repository so that we know which agents are readily available?"
NCI Response: In lieu of the list of studies mentioned on page 21 of the transcript the following list of agents from current DCP consortia trials is provided:
mailto:perryd@mail.nih.gov mailto:vd9t@nih.gov
- 2 -
Agent Name 3,3'-Diindolylmethane 4-Hydroxytamoxifen 9-cis-UAB30 Acolbifene.HCl Aminolevulinic Acid Hydrochloride Aspirin Atorvastatin Calcium Budesonide Celecoxib,Zileuton Cholecalciferol Curcumin Erlotinib.HCl Esomeprazole Magnesium Finasteride G-2535 (Isoflavones 100) Genistein Green Tea Catechins Inulin Letrozole Lovastatin L-Se-Methylselenocysteine l-Selenomethionine Lycopene Metformin Hydrochloride myo-Inositol Pioglitazone.HCl Polyethylene Glycol Resveratrol Rosiglitazone Maleate S-Adenosyl-l-methionine
SR13668
Sulindac Tamoxifen Citrate Ursodiol Veliparib
3. We would like to submit a proposal for an agent that has been submitted through to a cooperative group that was reviewed by DCP, but not related to the Chemoprevention Consortium contract. Would that be allowed?
NCI Response: If you have received feedback from DCP about a particular study, you should not submit it as a sample LOI. Also see page 43 of the transcript.
4. Regarding Article H.20 (page 26 of RFP) and question starting on page 41 of transcript: Given that RDC will not be used to collect data, does the data we do submit have to be encrypted? Secondly, do the security procedures outlined in this section apply to us?
NCI Response: Since the data will be submitted via Secure File Transfer Protocol (sFTP) the data will be secure and encryption is not needed. DCP will provide the sFTP site for Contractors.
Article H.20, Information and Physical Access Security (page 26 of RFP) applicability is pending. An amendment to this RFP addressing the applicability will be posted as soon as practicable.
- 3 -
5. Regarding the information needed from Subcontractors (page 90 of the RFP and related question on pages 6 & 48 of the transcript)
NCI Response: This response is intended to clarify what is needed from Offerors for subcontractor documentation:
In regards to page 90 of the RFP item 13: Provide the commitment letters from proposed subcontractors including the information outlined in item 13. a-e, and in addition, provide a description of the capabilities and strengths of the potential subcontractor, indicating why you are using them and what they can provide to the program. Although a complete budget from the potential subcontractor is not necessary (item 13.f), the Prime Offeror should budget for all anticipated costs (Core, Per Protocol and Per Subject costs) whether they will be delivered by the Prime or the subcontractor. All potential subcontractor costs should be indicated as such in the budget.
In addition to the requirements stated above regarding page 90, item 13 of the RFP, please provide the following:
a. Indirect rate agreement for each proposed subcontractor.
b. Written determination of prospective subcontractor's responsibility by the Offeror (see FAR Subpart 9.104-4).
c. Written determination of prospective subcontractor's financial responsibility by the Offeror to include a review of the prospective subcontractor's certified financial statements and accounting system.
d. Representations and Certifications for proposed subcontractors are required as indicated on page 47 of transcript.
e. Travel Policies for proposed subcontractors are not required as travel shall be proposed as prime contract Core costs only and therefore reside under the Prime Offerors' travel policy. See Additional Business Proposal Instructions in RFP. This supercedes the response on travel policies provided on page 47 of transcript.
FAR 9.104-4 Subcontractor responsibility
(a) Generally, prospective prime contractors are responsible for determining the responsibility of their prospective subcontractors (but see 9.405 and 9.405-2 regarding debarred, ineligible, or suspended firms). Determinations of prospective subcontractor responsibility may affect the Government's determination of the prospective prime contractor's responsibility. A prospective contractor may be required to provide written evidence of a proposed subcontractor's responsibility.
(b) When it is in the Government's interest to do so, the contracting officer may directly determine a prospective subcontractor's responsibility (e.g., when the prospective contract involves medical supplies, urgent requirements, or substantial subcontracting). In this case, the same standards used to determine a prime contractor's responsibility shall be used by the Government to determine subcontractor responsibility.
File details come from the government source that posted it. Updated .